Parent Alliance EBI serves as Hengrui Medicine's United States R&D center, enabling potential co-development or licensing partnerships for oncology and immunology programs while leveraging Hengrui's scale and global footprint.

Differentiated Discovery By combining target selection insights with structure-guided small molecule design, EBI accelerates lead optimization toward clinical candidates, presenting a compelling option for partners seeking first-in-class or best-in-class therapies in unmet medical needs.

Lean Outsourcing As a compact team of 2-10 employees, EBI offers a cost-efficient, agile platform for outsourced drug discovery activities such as lead optimization and SAR-driven design, enabling collaboration with mid-sized and larger pharmaceutical players.

US Presence Advantage Located in Cranbury, New Jersey, EBI benefits from proximity to North American biopharma networks, simplifying partner interactions, site visits, and engagement with the US market in oncology and immunology.

Licensing Growth With revenue in the mid-tens of millions, EBI demonstrates a validated business model and growth potential through licensing, co-development, or milestone-driven collaborations to monetize its discovery capabilities.